Search Results

• • 14 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Corrigendum

  From:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 201598 words Brief article, Corre... 1280LIn the Special Report by Alfredo Tartarone, Giuseppina Gallucci, Chiara Lazzari, Rosa Lerose, Lucia Lombardi & Michele Aieta, titled 'Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and...

• Role of imaging in testicular cancer: current and future practice

  Authors:Glen W Barrisford, Evgeniy I Kreydin, Mark A Preston, Dayron Rodriguez, Mukesh G Harisighani, and Adam S FeldmanFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20156,973 words Report 1570LAuthor(s): Glen W Barrisford aff1 , Evgeniy I Kreydin aff1 , Mark A Preston aff1 , Dayron Rodriguez aff1 , Mukesh G Harisighani aff2 , Adam S Feldman [*] aff1 KEYWORDS diagnostic imaging; testicular neoplasms;...

• The role of alisertib in treatment of peripheral T-cell lymphomas.

  Author:Eve Gallop-EvansFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20156,919 words Report 1800LPeripheral T-cell lymphomas are aggressive lymphomas with poor outcomes for which novel treatments are urgently needed. Alisertib (MLN8237) is a second-generation oral Aurora A kinase inhibitor. Treatment with alisertib...

• Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria

  Authors:Harry Raftopoulos, Ralph Boccia, William Cooper, Erin O'Boyle, and Richard J GrallaFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20155,566 words Report 1700LAuthor(s): Harry Raftopoulos [*] aff1 aff2 , Ralph Boccia aff3 , William Cooper aff4 , Erin O'Boyle aff5 , Richard J Gralla aff6 KEYWORDS APF530; cancer; chemotherapy-induced nausea and vomiting; extended-release;...

• Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer

  Authors:Roberto Petrioli, Giandomenico Roviello, Anna Ida Fiaschi, Letizia Laera, Salvatora Tindara Miano, Daniele Marrelli, et al.From:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20157,585 words Report 1830LAuthor(s): Roberto Petrioli [*] aff1 , Giandomenico Roviello aff1 , Anna Ida Fiaschi aff2 , Letizia Laera aff1 , Salvatora Tindara Miano aff1 , Daniele Marrelli aff3 , Franco Roviello aff4 , Vincenzo Bianco aff5 ,...

• Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer

  Authors:Diego Marquez-Medina and Sanjay PopatFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 201510,478 words Report 1630LAuthor(s): Diego Marquez-Medina aff1 , Sanjay Popat [*] aff2 KEYWORDS adenocarcinoma; afatinib; EGF receptor; ErbB2; ErbB4; irreversible; non-small-cell lung cancer; second generation; squamous; tyrosine kinase...

• Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients

  From:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20151,256 words Interview 2010LAuthor(s): Claire Thom [*] KEYWORDS acute myeloid leukemia; AML; ASP2215; Astellas; European Hematology Association Congress; FLT3 mutation Q How did you come to be in the role you are in today as Vice...

• Obinutuzumab in chronic lymphocytic leukemia

  Author:Jehan DupuisFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20157,697 words Report 1710LAuthor(s): Jehan Dupuis [*] aff1 KEYWORDS anti-CD20; chronic lymphocytic leukemia; infusion-related reactions; minimal residual disease; obinutuzumab The introduction of the anti-CD20 monoclonal antibody...

• Cancer-associated fibroblasts in pancreatic adenocarcinoma

  Authors:Boju Pan, Quan Liao, Zheyu Niu, Li Zhou, and Yupei ZhaoFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20155,416 words Report 2140LAuthor(s): Boju Pan aff1 , Quan Liao [*] aff1 , Zheyu Niu aff1 , Li Zhou aff1 , Yupei Zhao aff1 KEYWORDS CAFs; chemotherapy; CXCL12; pancreatic ductal adenocarcinoma; SPARC Pancreatic ductal adenocarcinoma...

• Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study

  Authors:Bruno Daniele, Adina Croitoru, Christos Papandreou, Jean-Pierre Bronowicki, Philippe Mathurin, Fatima Serejo, et al.From:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20154,687 words Report 1650LAuthor(s): Bruno Daniele [*] aff1 , Adina Croitoru aff2 , Christos Papandreou aff3 , Jean-Pierre Bronowicki aff4 , Philippe Mathurin aff5 , Fatima Serejo aff6 , Per Stål aff7 , Juan Turnes aff8 , Vlad Ratziu aff9 ,...

• Is dasatinib-related pulmonary hypertension a clinical concern?

  Author:Sebastian SzmitFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20152,402 words Editorial 1300LAuthor(s): Sebastian Szmit [*] aff1 KEYWORDS cardio-oncology; dasatinib; pleural effusion; pulmonary hypertension; sildenafil Basic clinical aspects Pulmonary arterial hypertension (PAH) seems to be a rare...

• Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development

  Authors:Marta Maleszewska and Bozena KaminskaFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 201510,770 words Report 1790LAuthor(s): Marta Maleszewska aff1 , Bozena Kaminska [*] aff1 KEYWORDS epi-drugs; gliomas; histone modifications; histone-modifying enzyme inhibitors; transcription regulation The state of chromatin and...

• Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients

  Authors:Bekir Hacioglu, Serkan Akin, Ali R Sever, and Kadri AltundagFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20151,644 words Editorial 1620LAuthor(s): Bekir Hacioglu aff1 , Serkan Akin aff1 , Ali R Sever aff2 , Kadri Altundag [*] aff1 KEYWORDS adjuvant; breast cancer; chemotherapy; complete remission; HER2-positive; intratumoral heterogeneity; locally...

• Curcumin as an anti-human papillomavirus and anti-cancer compound

  Authors:Alok Mishra and Bhudev C DasFrom:Future Oncology (Vol. 11, Issue 18) Peer-Reviewed

  Sept. 20152,324 words Editorial 2280LAuthor(s): Alok Mishra [*] aff1 aff2 , Bhudev C Das [**] aff1 aff2 aff3 KEYWORDS AP-1; cervical cancer; curcumin; HPV; NF-κB; oral cancers More than four decades ago, the link between human papillomavirus...